# A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

> **NCT02589275** · PHASE3 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 375 (actual)

## Conditions studied

- Primary Fibromyalgia

## Interventions

- **DRUG:** TNX-102 SL Tablet 2.8 mg

## Key facts

- **NCT ID:** NCT02589275
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-04
- **Primary completion:** 2016-09-28
- **Final completion:** 2016-09-28
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589275, "A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02589275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*